近五年主要论文

1.Wang J, Li Q, Qiu Y, Lu H. COVID-19: imbalanced cell-mediated immune response drives to immunopathology[J]. Emerging Microbes & Infections. 2022,11(1):2393-2404.

2.Zhang P, Ren T, Lu H, et al. A feasibility study of Covid-19 detection using breath analysis by high-pressure photon ionization time-of-flight mass spectrometry[J]. Journal of Breath Research. 2022,16(4):10.

3.Yang Y, Gong X, Lu H, et al. Comparative neutralization profiles of naive and breakthrough infections with Delta, Omicron BA.1 and BA.2 variants of SARS-CoV-2[J]. Signal Transduction and Targeted Therapy. 2022,7(1):316.

4.Liu X, Zhu Z, Miao Q, Lim JW, Lu H. Monkeypox-A danger approaching Asia[J]. BioScience Trends. 2022,16(4):245-248.

5.Liu X, Zhu Z, Lu H, et al. Monkeypox claims new victims: the outbreak in men who have sex with men[J]. Infectious Diseases of Poverty. 2022,23;11(1):84.

6.Liu X, Wang H, Zhu Z, Zhang L, Cao J, Zhang L, Yang H, Wen H, Hu Y, Chen C, Lu H. Exploring bridge symptoms in HIV-positive people with comorbid depressive and anxiety disorders[J]. BMC Psychiatry. 2022,22(1):448.

7.Yi C, Ling Z, Lu X, Fu Y, Yang Z, Wangmo S, Chen S, Zhang Y, Ma L, Gu W, Lu H, Sun X, Sun B. A SARS-CoV-2 antibody retains potent neutralization against Omicron by targeting conserved RBM residues[J]. Cellular & Molecular Immunology. 2022,19(5):647-649.

8.Su B, Yao C, Lu H, et al. Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study[J]. The Journal of infection. 2022,85(3):334-363.

9.Li X, Wu L, Qu Y, Cao M, Feng J, Huang H, Liu Y, Lu H, Liu Q, Liu Y. Clinical characteristics and vaccine effectiveness against SARS-CoV-2 Omicron subvariant BA.2 in the children[J]. Signal Transduction and Targeted Therap. 2022,7(1):203.

10.Yang S, Ling Y, Lu H, et al. Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression[J]. Signal Transduction and Targeted Therap. 2022,7(1):91.

11.Hu J, Gu L, Lu H, et al. Long-term case-fatality rate of nontuberculous mycobacterial disease in people living with HIV[J]. Infectious Diseases of Poverty. 2022;11(1):16.

12.Liu D, Gu L, Zhang R, Liu L, Shen Y, Shao Y, Wang J, Sun J, Qi T, Wang Z, Tang Y, Song W, Xun J, Lu H, Chen J. Utility of urine lipoarabinomannan (LAM) in diagnosing mycobacteria infection among hospitalized HIV-positive patients[J]. International Journal of Infectious Diseases. 2022,118:65-70.

13.Li W, Yang S, Lu H, et al. SARS-CoV-2 RNA elements share human sequence identity and upregulate hyaluronan via NamiRNA-enhancer network[J]. EBioMedicine. 2022,76:103861.

14.YangYang, Gong X, Yang L, et al. Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees[J].  The Journal of infection. 2022,84(4):579-613.

15.Wang Y, Liu M, Lu H, et al. Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses[J].Cell Discovery. 2022;8(1):36.

16.Li Q, Wang L, Wang B, Lu H. The COVID-19-designated hospitals in China: preparing for public health emergencies[J]. Emerging Microbes & Infections. 2021,10(1):998-1001.

17.Chen J, Liu D, Yin L, Zhang L, Lu H. Can we use hydroxychloroquine to treat COVID-19 now? [J] International Journal of Antimicrobial Agents. 2021,57(1):106173.

18.Bao Y, Ling Y, Lu H, et al. Dynamic anti-spike protein antibody profiles in COVID-19 patients[J]. International Journal of Infectious Diseases. 2021,103:540-548.

19.Chen J, Zhang R, Lu H, et al. Clinical usefulness of metagenomic next-generation sequencing for the diagnosis of central nervous system infection in people living with HIV[J]. International Journal of Infectious Diseases. 2021;107:139-144.

20.Stratton CW, Tang YW, Lu H. Pathogenesis-directed therapy of 2019 novel coronavirus disease[J]. Journal of medical virology. 2021,93(3):1320-1342.

21.Meng X, Wang P, Xiong Y, Wu Y, Lin X, Lu S, Li R, Zhao B, Liu J, Zeng S, Zeng L, Wu Y, Lu Y, Zhang J, Liu D, Wang S, Lu H. Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody[J]. Emerging Microbes & Infections. 2021,10(1):1638-1648.

22.Xie G, Ding F, Han L, Yin D, Lu H, Zhang M. The role of peripheral blood eosinophil counts in COVID-19 patients[J].Allergy. 2021,76(2):471-482.

23.Qiu C, Song Z, Wang J, Tian C, Liu X, Wu T, Li W, Zhang S, Lu H. Saliva specimen complements anal swab in assessing patients with COVID-19 for discharge from hospital[J]. Emerging Microbes & Infections. 2021,10(1):2090-2097.

24.Yi C, Sun X, Lin Y, Gu C, Ding L, Lu X, Yang Z, Zhang Y, Ma L, Gu W, Qu A, Zhou X, Li X, Xu J, Ling Z, Xie Y, Lu H, Sun B. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants[J]. Genome Medicine. 2021,13(1):164.

25. Tan Y, Zhang W, Zhu Z, Qiao N, Ling Y, Guo M, Yin T, Fang H, Xu X, Lu G, Zhang P, Yang S, Fu Z, Liang D, Xie Y, Zhang R, Jiang L, Yu S, Lu J, Jiang F, Chen J, Xiao C, Wang S, Chen S, Bian XW, Lu H, Liu F, Chen S. Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19[J]. Cell Discovery. 2021,7(1):42.

26. Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients[J]. Emerging Microbes & Infections. 2020,9(1):687-690.

27.Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, Xiong W, Yang D, Chen R, Lu F, Lu Y, Liu X, Chen Y, Li X, Li Y, Summah HD, Lin H, Yan J, Zhou M, Lu H, Qu J. COVID-19 with Different Severities: A Multicenter Study of Clinical Features[J]. American journal of respiratory and critical care medicine. 2020,201(11):1380-1388.

28.Chen J, Chen R, Shen Y, Wei H, Wang X, Zhang R, Hu Z, Xie R, Huang Q, Wang J, Liu L, Qi T, Wang Z, Song W, Tang Y, Sun J, Lu H. Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial[J].Emerging Microbes & Infections. 2020,9(1):843-850.

29.Yi Z, Ling Y, Zhang X, Chen J, Hu K, Wang Y, Song W, Ying T, Zhang R, Lu H, Yuan Z. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population[J]. Emerging Microbes & Infections. 2020,9(1):1988-1996.

30. Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, Jia X, Wu M, Shi B, Xu S, Chen J, Wang W, Chen B, Jiang L, Yu S, Lu J, Wang J, Xu M, Yuan Z, Zhang Q, Zhang X, Zhao G, Wang S, Chen S, Lu H. Viral and host factors related to the clinical outcome of COVID-19[J]. Nature. 2020,583(7816):437-440.

31. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, Li F, Xu Q, Zhang Y, Xu S, Song Z, Zeng Y, Shen Y, Shi Y, Zhu T, Lu H. Clinical progression of patients with COVID-19 in Shanghai, China[J]. The Journal of infection. 2020,80(5):e1-e6.

32. Lu H, Stratton CW, Tang YW. An evolving approach to the laboratory assessment of COVID-19[J]. Journal of medical virology. 2020,92(10):1812-1817.

33.Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle[J]. Journal of medical virology. 2020,92(4):401-402.

34. Shen Y, Zheng F, Sun D, Ling Y, Chen J, Li F, Li T, Qian Z, Zhang Y, Xu Q, Liu L, Huang Q, Shan F, Xu L, Wu J, Zhu Z, Song Z, Li S, Shi Y, Zhang J, Wu X, Mendelsohn JB, Zhu T, Lu H. Epidemiology and clinical course of COVID-19 in Shanghai, China[J]. Emerging Microbes & Infections. 2020,9(1):1537-1545.

35.Liu XH, Lu SH, Chen J, Xia L, Yang ZG, Charles S, Yang Y, Lin Y, Lu HZ. Clinical characteristics of foreign-imported COVID-19 cases in Shanghai, China[J]. Emerging Microbes & Infections. 2020,9(1):1230-1232.

36.Lu H, Stratton CW, Tang YW. An evolving approach to the laboratory assessment of COVID-19[J]. Journal of medical virology. 2020,92(10):1812-1817.

37. Fu W, Liu Y, Xia L, Li M, Song Z, Hu H, Yang Z, Wang L, Cheng X, Wang M, Jiang R, Liu L, Mao X, Chen J, Ling Y, Zhang L, Yan J, Shan F, Steinhart C, Zhang X, Zhu T, Xu J, Lu H. A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19[J]. EClinicalMedicine. 2020,25:100478.

38. Lu H, Stratton CW, Tang YW. The Wuhan SARS-CoV-2-What's next for China[J]. Journal of medical virology. 2020,92(6):546-547.

39.Lu H, Tang YW. Myths in the laboratory diagnosis of HIV infection[J]. Emerging Microbes & Infections. 2019,8(1):1240-1242.

40.Yang J, Chen J, Ji Y, Tang Q, Zhang R, Liu L, Shen Y, Xun J, Song W, Tang Y, Wang Z, Qi T, Lu H. Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients[J]. International journal of infectious diseases. 2019,83:64-71.

41.Sun Y, Xu L, Zhang F, Song Z, Hu Y, Ji Y, Shen J, Li B, Lu H, Yang H. A promising magnetic SERS immunosensor for sensitive detection of avian influenza virus[J]. Biosensors and Bioelectronics. 2017,89(Pt 2):906-912.

42.Ji YJ, Liang PP, Shen JY, Sun JJ, Yang JY, Chen J, Qi TK, Wang ZY, Song W, Tang Y, Liu L, Zhang RF, Shen YZ, Lu HZ. Risk factors affecting the mortality of HIV-infected patients with pulmonary tuberculosis in the cART era: a retrospective cohort study in China[J]. Infectious Diseases of Poverty. 2018,7(1):25.

43.Ji Y, Zhang F, Zhang R, Shen Y, Liu L, Wang J, Yang J, Tang Q, Xun J, Qi T, Wang Z, Song W, Tang Y, Chen J, Lu H. Changes in intestinal microbiota in HIV-1-infected subjects following cART initiation: influence of CD4+ T cell count[J].  Emerging Microbes & Infections. 2018,7(1):113.